2226636-04-8
Chemical Structure
Soquelitinib
Synonym(s): CPI-818
- CAS No.: 2226636-04-8
- Formula:C25H30N4O4S2
- Molecular Weight:514.66
InChIKey: KNCWSXRTKLTULH-MRXNPFEDSA-N
SMILES: O=C(N1C[C@H](N(CCC1)C(C=C)=O)C)C2=C(C=C(C(SC3=CN=C(NC(C4CC4)=O)S3)=C2)C)OC
Biological Activity: Soquelitinib (CPI-818) is an orally active and highly selective covalent interleukin-2-inducible kinase (ITK) inhibitor. Soquelitinib is active in six different models of T cell-mediated inflammatory and immune disease, including acute and chronic asthma, pulmonary fibrosis, systemic sclerosis (scleroderma), psoriasis, and acute graft versus host disease with Th2 cytokine product inhibition. Soquelitinib increases tumor infiltration of normal CD8+ cells that possess enhanced T effector function[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Soquelitinib | 99.98% | Soquelitinib (CPI-818) is an orally active and highly selective covalent interleukin-2-inducible kinase (ITK) inhibitor. Soquelitinib is active in six different models of T cell-mediated inflammatory and immune disease, including acute and chronic asthma, pulmonary fibrosis, systemic sclerosis (scleroderma), psoriasis, and acute graft versus host disease with Th2 cytokine product inhibition. Soquelitinib increases tumor infiltration of normal CD8+ cells that possess enhanced T effector function. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Hsu L Y, et al. Selective inhibition of interleukin-2 inducible T cell kinase (ITK) enhances anti-tumor immunity in association with Th1-skewing, cytotoxic T cell activation, and reduced T cell exhaustion[J]. bioRxiv, 2023: 2023.07. 05.547822.
- [2]. Ding N, et al. Dynamic Single-Cell Profiling Reveals Novel Immune Regulatory Mechanism of ITK Inhibitor Soquelitinib in Refractory T Cell Lymphoma [J]. Blood, 2023, 142: 1442.
- [3]. Hsu L Y, et al. Soquelitinb, A selective inhibitor of interleukin-2-inducible kinase (ITK), is active in several murine models of T cell-mediated inflammatory disease[J]. bioRxiv, 2023: 2023.10. 27.564296.
Keywords
